Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,411
  • Shares Outstanding, K 86,422
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,140 K
  • EBIT $ -26 M
  • EBITDA $ -25 M
  • 60-Month Beta 1.00
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.56
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.30
  • Most Recent Earnings $-0.06 on 05/14/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.09
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4500 +3.91%
on 05/16/25
0.6100 -23.34%
on 04/23/25
-0.1004 (-17.68%)
since 04/16/25
3-Month
0.4500 +3.91%
on 05/16/25
0.7782 -39.91%
on 02/18/25
-0.2996 (-39.05%)
since 02/14/25
52-Week
0.4500 +3.91%
on 05/16/25
1.5300 -69.44%
on 10/07/24
-0.6624 (-58.62%)
since 05/16/24

Most Recent Stories

More News
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on...

ONCY : 0.4676 (-6.54%)
ONC.TO : 0.65 (-5.80%)
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ:...

ONCY : 0.4676 (-6.54%)
ONC.TO : 0.65 (-5.80%)
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty

/CNW/ -- Equity Insider News Commentary – Optimism in the field of oncology is on the rise, thanks to the National Institutes of Health's latest annual report,...

ONCY : 0.4676 (-6.54%)
BCT.TO : 4.08 (+0.74%)
BCTXW : 0.0692 (+16.30%)
AZN : 68.81 (+1.25%)
STRO : 0.9116 (+3.77%)
BCTX : 2.94 (+0.68%)
ONC.TO : 0.65 (-5.80%)
TEM : 65.49 (+4.62%)
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will present new data...

ONCY : 0.4676 (-6.54%)
ONC.TO : 0.65 (-5.80%)
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

/CNW/ -- Equity Insider News Commentary – Routine medical appointments or cancer screenings—critical for catching the disease in earlier, more treatable...

ONCY : 0.4676 (-6.54%)
ONC : 228.38 (+1.16%)
CVM : 0.2230 (-3.59%)
ONC.TO : 0.65 (-5.80%)
ATNM : 1.6700 (+9.15%)
OSTX : 1.6400 (-1.20%)
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Routine medical appointments or cancer screening rates—an important aspect in increasing survival...

ONCY : 0.4676 (-6.54%)
URGN : 7.31 (-25.79%)
NVS : 109.59 (+1.04%)
PHIO : 1.8400 (+3.37%)
ONC.TO : 0.65 (-5.80%)
HURA : 3.92 (+2.08%)
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered into a...

ONCY : 0.4676 (-6.54%)
ONC.TO : 0.65 (-5.80%)
Private Sector Steps Up in Cancer Research as Federal Support Wavers

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As the Trump administration signals potential cuts to the National Institutes of Health (NIH), questions...

ONCY : 0.4676 (-6.54%)
SMMT : 23.87 (+3.38%)
CADL : 5.35 (+4.70%)
IMTX : 4.74 (+1.07%)
EXEL : 45.40 (-1.86%)
ONC.TO : 0.65 (-5.80%)
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discussed by...

ONCY : 0.4676 (-6.54%)
ONC.TO : 0.65 (-5.80%)
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

/CNW/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual...

ONCY : 0.4676 (-6.54%)
EXEL : 45.40 (-1.86%)
ONC.TO : 0.65 (-5.80%)
ALXO : 0.4374 (+0.37%)
CRDF : 2.81 (+2.18%)
VSTM : 7.59 (-4.29%)

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 0.5451
2nd Resistance Point 0.5225
1st Resistance Point 0.4951
Last Price 0.4676
1st Support Level 0.4451
2nd Support Level 0.4225
3rd Support Level 0.3951

See More

52-Week High 1.5300
Fibonacci 61.8% 1.1174
Fibonacci 50% 0.9900
Fibonacci 38.2% 0.8626
Last Price 0.4676
52-Week Low 0.4500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »